A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Open accessThe DOI matches its Crossref record.
Abstract
Chronic myeloid leukemia (CML) patients who relapse on imatinib due to acquired ABL1 kinase domain mutations are successfully treated with second-generation ABL1-tyrosine kinase inhibitors (ABL-TKIs) such as dasatinib, nilotinib or ponatinib. However, ~40% of relapsed patients have uncharacterized BCR-ABL1 kinase-independent mechanisms of resistance. To identify these mechanisms of resistance and potential treatment options, we generated ABL-TKI-resistant K562 cells through prolonged sequential exposure to imatinib and dasatinib. Dual-resistant K562 cells lacked BCR-ABL1 kinase domain mutations, but acquired other genomic aberrations that were characterized by next-generation sequencing and copy number analyses. Proteomics showed that dual-resistant cells had elevated levels of FOXO1, phospho-ERK and BCL-2, and that dasatinib no longer inhibited substrates of the PI3K/AKT pathway. In contrast to parental cells, resistant cells were sensitive to growth inhibition and apoptosis induced by the class I PI3K inhibitor, GDC-0941 (pictilisib), which also induced FOXO1 nuclear translocation. FOXO1 was elevated in a subset of primary specimens from relapsed CML patients lacking BCR-ABL1 kinase domain mutations, and these samples were responsive to GDC-0941 treatment ex vivo. We conclude that elevated FOXO1 contributes to BCR-ABL1 kinase-independent resistance experienced by these CML patients and that PI3K inhibition coupled with BCR-ABL1 inhibition may represent a novel therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The regulation of FOXO1 and its role in disease progression
Xing, Y.-Q., Li, A., Yang, Y., Li, X.-X., Zhang, L.-N., & Guo, H.-C. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.11.030 · Cited by 420
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 222
“Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, et al. A role for FOXO1 in BCR-ABL1independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.”
BackgroundAlves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Patel, A. B., O’Hare, T., & Deininger, M. W. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.04.007 · Cited by 204
Self-citationLei, H., Xu, H.-Z., Shan, H.-Z., Liu, M., Lu, Y., Fang, Z.-X., Jin, J., Jing, B., Xiao, X.-H., Gao, S.-M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20259-0 · Cited by 146
Metadata
- Authors
- Wagle, M., Eiring, A. M., Wongchenko, M., Lu, S., Guan, Y., Wang, Y., Lackner, M., Amler, L., Hampton, G., Deininger, M. W., O'Hare, T., & Yan, Y.
- Venue
- Leukemia
- Published
- 2016-03-08
- Volume
- 30
- Issue
- 7
- Pages
- 1493-1501
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2296146218
- Cited by
- 74
- References
- 0
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. https://app.cochat.ai/papers/10.1038/leu.2016.51
- The paper
- Wagle, M., Eiring, A. M., Wongchenko, M., Lu, S., Guan, Y., Wang, Y., Lackner, M., Amler, L., Hampton, G., Deininger, M. W., O'Hare, T., & Yan, Y. (2016). A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. https://doi.org/10.1038/leu.2016.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.